ImmunoMedics Should Be On Your Radar Before Phase 2 Breast Cancer Data Update


ImmunoMedics is nearing the first quarter of 2018 when it will file for its Biologics License Application to the FDA for accelerated approval of IMMU-132. Early phase 2 data in Metastatic Triple-Negative Breast cancer patients already achieved over the threshold set by the FDA for accelerated approval for this patient population.



from Biotech News